Helus Pharma Adds Neuroscience Veteran to Medical Leadership Team
Event summary
- Helus Pharma appoints Dr. Ken Kramer as Senior Vice President, Medical Affairs, effective April 16, 2026.
- Dr. Kramer brings 25 years of neuroscience experience, including leading global medical launches at Bristol Myers Squibb and Karuna Therapeutics.
- Helus Pharma is developing HLP003 (Phase 3) for major depressive disorder and HLP004 (Phase 2) for generalized anxiety disorder.
- HLP003 has received Breakthrough Therapy Designation from the FDA.
The big picture
Helus Pharma’s appointment of Dr. Ken Kramer underscores its focus on strengthening medical leadership to support its neuroscience pipeline. The move comes as the company advances its proprietary NSAs through critical clinical phases, aiming to address significant unmet needs in mental health. The neuroscience sector is increasingly competitive, with companies like Bristol Myers Squibb and Karuna Therapeutics also vying for leadership in novel treatments for neuropsychiatric disorders.
What we're watching
- Clinical Execution
- How Dr. Kramer’s experience will accelerate Helus Pharma’s Phase 3 and Phase 2 programs.
- Regulatory Dynamics
- Whether the Breakthrough Therapy Designation for HLP003 will streamline approval timelines.
- Market Differentiation
- The pace at which Helus Pharma can establish NSAs as a differentiated treatment approach in neuropsychiatry.
Related topics